Investment Rating - The report maintains an "Outperform" rating for Q Technology (01478) [1] Core Insights - Q Technology is expected to achieve a 435% year-on-year increase in net profit for 2025, which is at the high end of the profit forecast [1] - Adjusted net profit, excluding disposal gains, is projected to grow by 144% to 682 million RMB [1] - The shipment volume and revenue from non-mobile camera modules for 2025 are both expected to exceed company guidance, with strong growth anticipated to continue into 2026 [1] - Despite facing adverse industry factors, the company expects mobile camera module shipments to increase by over 5% year-on-year [1] Summary by Relevant Sections - **Profit Forecast**: Q Technology's net profit is forecasted to grow significantly, with a 435% increase expected for 2025, aligning with the upper range of profit predictions [1] - **Adjusted Profit**: The adjusted net profit, after excluding one-time gains, is anticipated to reach 682 million RMB, reflecting a substantial 144% growth year-on-year [1] - **Product Performance**: The company is projecting higher-than-guided shipment volumes and revenues for non-mobile camera modules, indicating robust performance and growth potential into 2026 [1] - **Market Outlook**: The company remains optimistic about the mobile camera module market, forecasting a shipment increase of over 5% despite industry challenges [1]

Investment Rating - The report upgrades the investment rating of Bilibili (BILI.US) and Bilibili-W (09626) to "Overweight" [1] Core Insights - The target price for Bilibili's US stock is raised from $27 to $35, while the target price for its Hong Kong stock is increased from HKD 210 to HKD 270 [1] - The report suggests that investors should take advantage of the current low stock price, as the company's strategy to increase AI investments is deemed correct [1] - AI has already become a driving factor for user engagement and advertising revenue growth, and this trend is expected to continue in the coming years [1] - The company is projected to achieve steady profit growth this year, supported by strong operational leverage, even with AI investments [1] - Adjusted net profit is expected to grow by 25% in 2025, accelerating to 41% and 30% in 2027 and 2028, respectively [1] - A recent reduction in App Store commission rates by Apple is anticipated to positively impact several of Bilibili's business segments, with an estimated positive effect of about 3% [1]

Investment Rating - The report assigns a rating of "In Line with Market" for Ningde Times (03750) [1] Core Insights - Morgan Stanley has updated the risk-reward forecast for Ningde Times, noting that the company's performance last year exceeded expectations by 7%, leading to an upward revision of profit forecasts for this year and beyond [1] - The company has shown stronger net cash position than anticipated due to improved capital efficiency [1] - The report has also raised the assumptions for the company's energy storage battery shipments, reflecting potential opportunities driven by demand growth from AI data centers amid a global power capacity shortage [1] - Based on the EV/EBITDA method and the appreciation of the Renminbi, Morgan Stanley has increased the target price for Ningde Times' H-shares by 12%, from HKD 585 to HKD 655 [1]

Investment Rating - The investment rating for Li Auto-W (02015) has been downgraded from "Buy" to "Neutral" by Goldman Sachs [1] Core Insights - Li Auto's Q4 2025 performance met expectations, but the guidance for Q1 2026 and the full year is below expectations in terms of sales and gross margin [1] - Goldman Sachs has lowered the target price for Li Auto from HKD 93 to HKD 74, anticipating a continuous expansion of net losses over the next two quarters due to weak sales growth and pressure on vehicle gross margins [1] - The decline in performance is attributed to a lack of new model launches, rising raw material and memory costs, and an increased proportion of low-margin models [1] Sales and Margin Forecasts - Sales forecasts for 2026 to 2028 have been reduced by 5% to 22%, based on management's lower-than-expected sales guidance for 2026 and a slowdown in the launch of refreshed models [1] - Gross margin forecasts have been adjusted downwards by 0.4 to 1.0 percentage points, reflecting the lower-than-expected guidance for Q1 2026 and the full year, along with decreased sales and revenue [1] - Consequently, net profit forecasts have been cut by 21% to 34% [1]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 77.60 [6]. Core Views - The company reported a revenue of HKD 7.71 billion for 2025, a decrease of 16.1% year-on-year, primarily due to a reduction in interest income from loans to associated companies. However, the net profit attributable to shareholders was HKD 6.236 billion, reflecting a year-on-year increase of 1.9%, which is in line with expectations [1][4]. - The company is expected to benefit from an increase in return rates for several regulated assets entering new regulatory periods in 2026, which supports future earnings growth. The sale of UK Power Networks (UKPN) is anticipated to significantly enhance cash reserves and improve the company's capacity for global expansion and acquisitions [3][4]. - The Australian business contributed a profit of HKD 1.461 billion in 2025, up 4% year-on-year, driven by regulatory changes allowing for a return rate increase. The Hong Kong business remained stable, contributing HKD 1.051 billion, while the UK business's profit contribution was flat due to high base effects from the previous year [2][3]. Summary by Sections Financial Performance - The company achieved a revenue of HKD 7.71 billion in 2025, down 16.1% year-on-year. The net profit attributable to shareholders was HKD 6.236 billion, up 1.9% year-on-year. The dividend per share (DPS) for 2025 is HKD 2.82, maintaining a dividend payout ratio of 96% [1][4]. - The projected net profits for 2026-2028 are HKD 7.159 billion, HKD 7.264 billion, and HKD 7.561 billion, respectively, indicating a growth trajectory [4][9]. Regulatory Changes and Future Outlook - Several regulated assets are entering new regulatory periods in 2026, which is expected to lead to increased return rates. For instance, Northumbrian Water's return rate is set to increase by 0.83 percentage points to 4.03% [3]. - The company anticipates that the UKPN equity sale will be completed by the end of June 2026, potentially generating a profit contribution of approximately HKD 3 billion [2][4]. Valuation Metrics - The report estimates the company's price-to-book (PB) ratio at 1.80x for 2026, with a target price of HKD 77.60, reflecting a positive outlook based on historical averages and expected performance improvements [4][9].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% against the benchmark index within the next 6 to 12 months [12] Core Insights - The company achieved a revenue of 64.73 billion yuan in 2025, representing a year-on-year growth of 101.3%. The gross margin reached a record high of 14.5%, up by 6.1 percentage points year-on-year, with a quarterly gross margin of 15% in Q4 2025 [5][6] - The company turned profitable in 2025 with a net profit of 540 million yuan, marking a significant turnaround from previous losses [5][6] - The company is set to launch new models in 2026, including the A series and D series, which are expected to fill gaps in the current product lineup and contribute to increased sales [8] Financial Performance Summary - Revenue projections for the company are as follows: 32.16 billion yuan in 2024, 64.73 billion yuan in 2025, 100.81 billion yuan in 2026, 138.68 billion yuan in 2027, and 163.5 billion yuan in 2028, with growth rates of 92%, 101%, 56%, 38%, and 18% respectively [4] - The company’s net profit is projected to reach 4.82 billion yuan in 2026, 7.35 billion yuan in 2027, and 9.25 billion yuan in 2028, with year-on-year growth rates of 796%, 52%, and 26% respectively [4] - The earnings per share (EPS) is expected to be 0.38 yuan in 2025, 3.39 yuan in 2026, 5.17 yuan in 2027, and 6.51 yuan in 2028 [4] Market Position and Expansion - The company ranked first among new energy vehicle manufacturers in terms of export volume, with 67,000 vehicles exported in 2025 and over 100,000 cumulative exports by February 2026 [7] - The company is actively expanding into the South American market, with new models launched in Brazil and plans for further growth in this region [7] Future Outlook - The introduction of the A and D series models is anticipated to drive domestic sales upward, while the new factory in Spain is expected to commence production of the B10 model in October 2026 [8] - Despite adjustments in profit forecasts due to industry challenges, the company is expected to maintain strong growth driven by new vehicle cycles and international expansion [8]

Investment Rating - The report maintains a "Buy" rating for MONGOL MINING (0975.HK) [3] Core Views - The company is expected to experience a short-term bottoming in performance, with gold production opening up growth opportunities [1] - In 2025, the company reported total revenue of $823 million, a decrease of 20.8% year-on-year, and a net profit attributable to shareholders of $6 million, down 97.5% year-on-year [9] - The decline in profits is primarily attributed to a decrease in the average selling price of washed coking coal products and a one-time loss of $25.049 million from the early redemption of priority notes due in 2026 [9] - The company’s coal production volume decreased by 10.2% year-on-year to 14.67 million tons, while sales volume increased by 17.4% year-on-year to 10.1 million tons [9] - The average selling price of coal fell by 35.1% year-on-year to $78.4 per ton, with significant declines in the prices of washed coking coal and other coal types [9] - The company is expected to benefit from the production ramp-up of the BKH gold mine, which is projected to contribute $77 million in net profit in 2026 [9] - The Mongolian government's revenue-sharing policy details are expected to be clarified by the end of June 2026, which may provide more predictable cash flow benefits [9] Financial Forecasts - Revenue projections for 2025 to 2028 are $823 million, $1.228 billion, $1.430 billion, and $1.497 billion, respectively, with growth rates of -20.8%, 49.2%, 16.4%, and 4.6% [3][10] - Net profit attributable to shareholders is forecasted to be $6 million in 2025, $186 million in 2026, $300 million in 2027, and $337 million in 2028, with growth rates of -97.5%, 2944.0%, 61.8%, and 12.1% [3][10] - The earnings per share (EPS) is projected to be $0.01 in 2025, $0.18 in 2026, $0.29 in 2027, and $0.32 in 2028 [3][10] - The price-to-earnings (P/E) ratio is expected to decrease from 226 in 2025 to 4 in 2028, while the price-to-book (P/B) ratio is projected to decline from 1.1 to 0.7 over the same period [3][10]

Investment Rating - The investment rating for the company is "Buy" [6][10]. Core Insights - The company has experienced significant revenue growth, with a net profit turnaround, particularly in overseas markets where revenue increased nearly fourfold [2][10]. - The company's total revenue for 2025 reached 29.13 billion RMB, a year-on-year increase of 30.0%, while the net profit was 634 million RMB, marking a return to profitability [10]. - The gross profit margin for 2025 was 46.8%, a decrease of 5.8 percentage points year-on-year, attributed to increased mold investments for new product categories [10]. Financial Summary - Total Revenue (Million RMB): - 2024: 2,241 - 2025: 2,913 - 2026E: 3,800 - 2027E: 4,750 - 2028E: 6,000 - Growth Rates: 156% (2024-2025), 30% (2025-2026), 30% (2026-2027), 25% (2027-2028) [4][11]. - Net Profit (Million RMB): - 2024: (401) - 2025: 634 - 2026E: 764 - 2027E: 922 - 2028E: 1,108 - Growth Rates: 258% (2025-2026), 20% (2026-2027), 20% (2027-2028) [4][11]. - PE Ratio: - 2025: 24.1 - 2026E: 20.0 - 2027E: 16.6 - 2028E: 13.8 [4][11]. Market Performance - The company's stock price has fluctuated between 53.40 and 193.30 HKD over the past 52 weeks, with a current market capitalization of 15.84 billion HKD [7][10]. Overseas Market Expansion - The company has focused on expanding its overseas market, achieving a revenue of 319 million RMB in 2025, a year-on-year increase of 396.6%, which now accounts for 10.9% of total revenue [10]. - The Asia-Pacific region (excluding China) generated 133 million RMB, up 238.1%, while the Americas saw revenue of 150 million RMB, an increase of 804.1% [10]. Future Outlook - The company aims to continue its focus on overseas markets, particularly in developed countries like the United States and Japan, while refining operations in Southeast Asia [10]. - Resources will be allocated primarily to product lines with predictable growth, such as building vehicles and IP series, while also exploring new opportunities [10].

Investment Rating - The report maintains a "Buy" rating for the company, with a current price of 15.99 HKD and a target value of 20.53 HKD [4]. Core Insights - The company is experiencing a resilient growth in its manufacturing business, while its retail segment is currently under pressure. The company continues to provide high dividends, with a total dividend of 1.3 HKD per share for the year, resulting in a payout ratio of 70% [8]. - For FY25, the company reported a revenue of 8.03 billion USD, a decrease of 1.8% year-on-year, and a net profit of 381 million USD, down 2.9% year-on-year [8]. - The manufacturing segment's revenue reached 5.65 billion USD, showing a slight increase of 0.5% year-on-year, despite a 1.2% decline in shipment volume. The average selling price (ASP) increased by 3.7% due to an optimized product mix [8]. - The retail business faced challenges, with revenue declining by 7.0% to 2.38 billion USD. However, online sales showed resilience, with Douyin sales increasing by over 70% [8]. Financial Projections - Revenue and profit forecasts for FY26 to FY28 are as follows: - Revenue: 8.35 billion USD (2026E), 8.68 billion USD (2027E), 8.97 billion USD (2028E) [2]. - Net profit: 388 million USD (2026E), 422 million USD (2027E), 449 million USD (2028E) [2]. - Earnings per share (EPS) is projected to be 0.24 USD (2026E), 0.26 USD (2027E), and 0.28 USD (2028E) [2]. - The report indicates a steady EBITDA forecast, with values of 857 million USD (2026E), 873 million USD (2027E), and 904 million USD (2028E) [2]. Business Segment Performance - Manufacturing business: - Revenue growth of 0.5% year-on-year, with a capacity utilization rate maintained at 93% [8]. - The gross margin for the manufacturing segment decreased by 1.7 percentage points due to fluctuating orders and rising labor costs [8]. - Retail business: - Revenue decline of 7.0% year-on-year, with a gross margin of 33.5%, down 0.7 percentage points [8]. - The number of direct-operated stores decreased by 4.0% to 3,310, with same-store sales declining between 10% to 20% [8]. Valuation Metrics - The report provides valuation metrics including: - Price-to-earnings (P/E) ratio projected to decrease from 9.1 (2024A) to 7.3 (2028E) [2]. - Return on equity (ROE) expected to slightly decline from 8.8% (2024A) to 9.0% (2028E) [2]. - EV/EBITDA ratio projected to decrease from 3.5 (2024A) to 3.3 (2028E) [2].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 8.212 billion yuan for 2025, representing a year-on-year growth of 9.9%, with normalized annual profit reaching 1.776 billion yuan, a 3.6% increase [1] - The revenue structure is optimizing, with exclusive/brand and innovative products accounting for 59.8% of sales, showing a significant year-on-year growth of 23.3% [2] - The company has six self-developed innovative pipelines in clinical development, indicating a strong focus on global hot targets in the pharmaceutical industry [3] - The company is expanding its innovation landscape through collaborations and investments, with several products expected to be approved in 2026 [3] - Revenue forecasts for 2026-2028 are projected at 9.937 billion yuan, 12.123 billion yuan, and 14.911 billion yuan, with corresponding growth rates of approximately 21%, 22%, and 23% [4] Revenue Structure - The company's revenue from exclusive/brand and innovative products reached 5.613 billion yuan, with a growth rate of 23.3% [2] - The revenue from exclusive and innovative drugs grew at a rate of 44.1%, indicating a transition to high-value products [2] Financial Projections - The expected net profit for 2026 is 2.178 billion yuan, with a growth rate of 46% [4] - The gross margin is projected to be 73.45% in 2026, slightly increasing from 71.50% in 2025 [5] - The return on equity (ROE) is expected to rise to 11.13% in 2026 [5] Clinical Development - The company has six self-developed innovative products in clinical development, including TYK2 inhibitors and GLP-1R/GCGR dual agonists [3] - Collaborations with other companies are expected to enhance the product pipeline and market reach [3]